Victory Capital Management Inc. Sells 42,851 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Victory Capital Management Inc. reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 50.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,934 shares of the medical equipment provider’s stock after selling 42,851 shares during the period. Victory Capital Management Inc. owned approximately 0.09% of BioLife Solutions worth $1,050,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of BioLife Solutions by 11.5% in the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after acquiring an additional 296,727 shares in the last quarter. Fred Alger Management LLC boosted its holdings in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after acquiring an additional 88,840 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of BioLife Solutions by 9.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after acquiring an additional 66,422 shares in the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter worth approximately $8,592,000. Finally, Meros Investment Management LP boosted its holdings in shares of BioLife Solutions by 1.7% in the 2nd quarter. Meros Investment Management LP now owns 399,803 shares of the medical equipment provider’s stock worth $8,568,000 after acquiring an additional 6,586 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Craig Hallum boosted their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reduced their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities upped their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the sale, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 3.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,644 shares of company stock worth $1,527,503. Insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $27.16 on Thursday. The firm has a fifty day moving average of $24.09 and a two-hundred day moving average of $23.14. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -25.53 and a beta of 1.88. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.